Short Telomeres Limit Tumor Progression In Vivo by Inducing Senescence

Cancer Cell

Volumn 11, Issue 5, 2007, Pages 461-469

  Feldser, David M ^a   Greider, Carol W ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CELLCYCLE

Indexed keywords

PROTEIN BCL 2; PROTEIN P53; TELOMERASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BURKITT LYMPHOMA; CANCER INHIBITION; CARCINOGENESIS; CONTROLLED STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENESCENCE; TELOMERE; TRANSGENIC MOUSE; TUMOR CELL; TUMOR GROWTH;

ANIMALIA; MUS; MUS MUSCULUS;

EID: 34247581288     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2007.02.026     Document Type: Article

References (40)

1. Adams J.M., Harris A.W., Pinkert C.A., Corcoran L.M., Alexander W.S., Cory S., Palmiter R.D., and Brinster R.L. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 318 (1985) 533-538
2. Artandi S.E., Chang S., Lee S.L., Alson S., Gottlieb G.J., Chin L., and DePinho R.A. Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice. Nature 406 (2000) 641-645
3. Blasco M.A., Lee H.W., Hande M.P., Samper E., Lansdorp P.M., DePinho R.A., and Greider C.W. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell 91 (1997) 25-34
4. Bodnar A.G., Ouellette M., Frolkis M., Holt S.E., Chiu C.P., Morin G.B., Harley C.B., Shay J.W., Lichtsteiner S., and Wright W.E. Extension of life-span by introduction of telomerase into normal human cells. Science 279 (1998) 349-352
5. Braig M., Lee S., Loddenkemper C., Rudolph C., Peters A.H., Schlegelberger B., Stein H., Dorken B., Jenuwein T., and Schmitt C.A. Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 436 (2005) 660-665
6. Chen Z., Trotman L.C., Shaffer D., Lin H.K., Dotan Z.A., Niki M., Koutcher J.A., Scher H.I., Ludwig T., Gerald W., et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436 (2005) 725-730
7. Chin L., Artandi S.E., Shen Q., Tam A., Lee S.L., Gottlieb G.J., Greider C.W., and DePinho R.A. p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell 97 (1999) 527-538
8. Collado M., Gil J., Efeyan A., Guerra C., Schuhmacher A.J., Barradas M., Benguria A., Zaballos A., Flores J.M., Barbacid M., et al. Tumour biology: Senescence in premalignant tumours. Nature 436 (2005) 642
9. Collado M., and Serrano M. The power and the promise of oncogene-induced senescence markers. Nat. Rev. Cancer 6 (2006) 472-476
10. d'Adda di Fagagna F., Reaper P.M., Clay-Farrace L., Fiegler H., Carr P., Von Zglinicki T., Saretzki G., Carter N.P., and Jackson S.P. A DNA damage checkpoint response in telomere-initiated senescence. Nature 426 (2003) 194-198
11. DeFranco A.L., Locksley R.M., and Robertson M. Immunity: The Immune Response in Infectious and Inflammatory Disease (2007), New Science Press, London
12. Denchi E., Celli G.B., and de Lange T. Hepatocytes with extensive telomere deprotection and fusion remain viable and regenerate liver mass through endoreduplication. Genes Dev. 20 (2006) 2648-2653
13. Dimri G.P., Lee X., Basile G., Acosta M., Scott G., Roskelley C., Medrano E.E., Linskens M., Rubelj I., Pereira-Smith O., et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl. Acad. Sci. USA 92 (1995) 9363-9367
14. Eischen C.M., Weber J.D., Roussel M.F., Sherr C.J., and Cleveland J.L. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev. 13 (1999) 2658-2669
15. Feldser D., Strong M.A., and Greider C.W. Ataxia telangiectasia mutated (Atm) is not required for telomerase-mediated elongation of short telomeres. Proc. Natl. Acad. Sci. USA 103 (2006) 2249-2251
16. Gonzalez-Suarez E., Samper E., Flores J.M., and Blasco M.A. Telomerase-deficient mice with short telomeres are resistant to skin tumorigenesis. Nat. Genet. 26 (2000) 114-117
17. Greenberg R.A., Chin L., Femino A., Lee K.H., Gottlieb G.J., Singer R.H., Greider C.W., and DePinho R.A. Short dysfunctional telomeres impair tumorigenesis in the INK4a(delta2/3) cancer-prone mouse. Cell 97 (1999) 515-525
18. Hao L.Y., Strong M.A., and Greider C.W. Phosphorylation of H2AX at short telomeres in T cells and fibroblasts. J. Biol. Chem. 279 (2004) 45148-45154
19. Harley C.B., Futcher A.B., and Greider C.W. Telomeres shorten during ageing of human fibroblasts. Nature 345 (1990) 458-460
20. Hemann M.T., Rudolph K.L., Strong M.A., DePinho R.A., Chin L., and Greider C.W. Telomere dysfunction triggers developmentally regulated germ cell apoptosis. Mol. Biol. Cell 12 (2001) 2023-2030
21. Hemann M.T., Strong M.A., Hao L.Y., and Greider C.W. The shortest telomere, not average telomere length, is critical for cell viability and chromosome stability. Cell 107 (2001) 67-77
22. Jacks T., Remington L., Williams B.O., Schmitt E.M., Halachmi S., Bronson R.T., and Weinberg R.A. Tumor spectrum analysis in p53-mutant mice. Curr. Biol. 4 (1994) 1-7
23. Lansdorp P.M., Verwoerd N.P., van de Rijke F.M., Dragowska V., Little M.T., Dirks R.W., Raap A.K., and Tanke H.J. Heterogeneity in telomere length of human chromosomes. Hum. Mol. Genet. 5 (1996) 685-691
24. Lechel A., Satyanarayana A., Ju Z., Plentz R.R., Schaetzlein S., Rudolph C., Wilkens L., Wiemann S.U., Saretzki G., Malek N.P., et al. The cellular level of telomere dysfunction determines induction of senescence or apoptosis in vivo. EMBO Rep. 6 (2005) 275-281
25. Lee H.W., Blasco M.A., Gottlieb G.J., Horner II J.W., Greider C.W., and DePinho R.A. Essential role of mouse telomerase in highly proliferative organs. Nature 392 (1998) 569-574
26. Liyanage M., Coleman A., du Manoir S., Veldman T., McCormack S., Dickson R.B., Barlow C., Wynshaw-Boris A., Janz S., Wienberg J., et al. Multicolour spectral karyotyping of mouse chromosomes. Nat. Genet. 14 (1996) 312-315
27. Lowe S.W., Cepero E., and Evan G. Intrinsic tumour suppression. Nature 432 (2004) 307-315
28. Martins C.P., Brown-Swigart L., and Evan G.I. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 127 (2006) 1323-1334
29. Michaloglou C., Vredeveld L.C., Soengas M.S., Denoyelle C., Kuilman T., van der Horst C.M., Majoor D.M., Shay J.W., Mooi W.J., and Peeper D.S. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436 (2005) 720-724
30. Parrinello S., Samper E., Krtolica A., Goldstein J., Melov S., and Campisi J. Oxygen sensitivity severely limits the replicative lifespan of murine fibroblasts. Nat. Cell Biol. 5 (2003) 741-747
31. Qi L., Strong M.A., Karim B.O., Armanios M., Huso D.L., and Greider C.W. Short telomeres and ataxia-telangiectasia mutated deficiency cooperatively increase telomere dysfunction and suppress tumorigenesis. Cancer Res. 63 (2003) 8188-8196
32. Qi L., Strong M.A., Karim B.O., Huso D.L., and Greider C.W. Telomere fusion to chromosome breaks reduces oncogenic translocations and tumour formation. Nat. Cell Biol. 7 (2005) 706-711
33. Rudolph K.L., Millard M., Bosenberg M.W., and DePinho R.A. Telomere dysfunction and evolution of intestinal carcinoma in mice and humans. Nat. Genet. 28 (2001) 155-159
34. Satyanarayana A., Wiemann S.U., Buer J., Lauber J., Dittmar K.E., Wustefeld T., Blasco M.A., Manns M.P., and Rudolph K.L. Telomere shortening impairs organ regeneration by inhibiting cell cycle re-entry of a subpopulation of cells. EMBO J. 22 (2003) 4003-4013
35. Schmitt C.A., McCurrach M.E., de Stanchina E., Wallace-Brodeur R.R., and Lowe S.W. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev. 13 (1999) 2670-2677
36. Schmitt C.A., Fridman J.S., Yang M., Baranov E., Hoffman R.M., and Lowe S.W. Dissecting p53 tumor suppressor functions in vivo. Cancer Cell 1 (2002) 289-298
37. Ventura A., Kirsch D.G., McLaughlin M.E., Tuveson D.A., Grimm J., Lintault L., Newman J., Reczek E.E., Weissleder R., and Jacks T. Restoration of p53 function leads to tumour regression in vivo. Nature 445 (2007) 661-665
38. Vogelstein B., Lane D., and Levine A.J. Surfing the p53 network. Nature 408 (2000) 307-310
39. Wong K.K., Maser R.S., Bachoo R.M., Menon J., Carrasco D.R., Gu Y., Alt F.W., and DePinho R.A. Telomere dysfunction and Atm deficiency compromises organ homeostasis and accelerates ageing. Nature 421 (2003) 643-648
40. Xue W., Zender L., Miething C., Dickins R.A., Hernando E., Krizhanovsky V., Cordon-Cardo C., and Lowe S.W. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445 (2007) 656-660